Tim Karl

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/2348945/tim-karl-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

118 60 4,126 38 h-index g-index citations papers 4,668 122 4.5 5.72 avg, IF L-index ext. citations ext. papers

#	Paper	IF	Citations
118	Cannabidiol (CBD) treatment improves spatial memory in 14-month-old female TAU58/2 transgenic mice <i>Behavioural Brain Research</i> , 2022 , 425, 113812	3.4	1
117	Mouse model of Alzheimer's disease demonstrates differential effects of early disease pathology on various brain regions. <i>Proteomics</i> , 2021 , 21, e2000213	4.8	1
116	Effects of handling on the behavioural phenotype of the neuregulin 1 type III transgenic mouse model for schizophrenia. <i>Behavioural Brain Research</i> , 2021 , 405, 113166	3.4	O
115	Behavioural effects of cage systems on the G93A Superoxide Dismutase 1 transgenic mouse model for amyotrophic lateral sclerosis. <i>Genes, Brain and Behavior</i> , 2021 , 20, e12735	3.6	
114	Spatial Memory and Microglia Activation in a Mouse Model of Chronic Neuroinflammation and the Anti-inflammatory Effects of Apigenin. <i>Frontiers in Neuroscience</i> , 2021 , 15, 699329	5.1	3
113	Cross-Linking Cellular Prion Protein Induces Neuronal Type 2-Like Hypersensitivity. <i>Frontiers in Immunology</i> , 2021 , 12, 639008	8.4	1
112	The behavioural phenotype of 14-month-old female TAU58/2 transgenic mice. <i>Behavioural Brain Research</i> , 2021 , 397, 112943	3.4	1
111	Sex-specific sensitivity to methamphetamine-induced schizophrenia-relevant behaviours in overexpressing mice. <i>Journal of Psychopharmacology</i> , 2021 , 35, 50-64	4.6	4
110	Characterisation of the Mouse Cerebellar Proteome in the GFAP-IL6 Model of Chronic Neuroinflammation. <i>Cerebellum</i> , 2021 , 1	4.3	1
109	CuATSM improves motor function and extends survival but is not tolerated at a high dose in SOD1 mice with a C57BL/6 background. <i>Scientific Reports</i> , 2021 , 11, 19392	4.9	1
108	Treatment of microglia with Anti-PrP monoclonal antibodies induces neuronal apoptosis <i>Heliyon</i> , 2021 , 7, e08644	3.6	O
107	Onset of hippocampal network aberration and memory deficits in P301S tau mice are associated with an early gene signature. <i>Brain</i> , 2020 , 143, 1889-1904	11.2	5
106	T177. CANNABIDIOL AS A POTENTIAL PREVENTATIVE TREATMENT IN A NEUREGULIN-1 MOUSE MODEL OF SCHIZOPHRENIA. <i>Schizophrenia Bulletin</i> , 2020 , 46, S298-S299	1.3	78
105	Chronic cannabidiol (CBD) treatment did not exhibit beneficial effects in 4-month-old male TAU58/2 transgenic mice. <i>Pharmacology Biochemistry and Behavior</i> , 2020 , 196, 172970	3.9	4
104	Chronic Treatment with 50 mg/kg Cannabidiol Improves Cognition and Moderately Reduces A🛭 0 Levels in 12-Month-Old Male A🎖 Pswe/PS1 🖺 9 Transgenic Mice. <i>Journal of Alzheimers: Disease</i> , 2020 , 74, 937-950	4.3	14
103	Novel Behavioural Characteristics of Male Human P301S Mutant Tau Transgenic Mice - A Model for Tauopathy. <i>Neuroscience</i> , 2020 , 431, 166-175	3.9	3
102	Medium-Dose Chronic Cannabidiol Treatment Reverses Object Recognition Memory Deficits of Transgenic Female Mice. <i>Frontiers in Pharmacology</i> , 2020 , 11, 587604	5.6	6

1	101	M91. ADDICTION-RELEVANT BEHAVIOURS FOR COCAINE IN A NEUREGULIN 1 MUTANT MOUSE MODEL OF SCHIZOPHRENIA. <i>Schizophrenia Bulletin</i> , 2020 , 46, S169-S169	1.3	78	
1	100	Cannabidiol (CBD) reduces cocaine-environment memory in mice. <i>Pharmacology Biochemistry and Behavior</i> , 2020 , 199, 173065	3.9	11	
Ş	99	Behavioural effects of high fat diet in adult Nrg1 type III transgenic mice. <i>Behavioural Brain Research</i> , 2020 , 377, 112217	3.4	5	
Ç	98	Novel behavioural characteristics of the superoxide dismutase 1 G93A (SOD1) mouse model of amyotrophic lateral sclerosis include sex-dependent phenotypes. <i>Genes, Brain and Behavior</i> , 2020 , 19, e12604	3.6	5	
9	97	Upregulation of Proteolytic Pathways and Altered Protein Biosynthesis Underlie Retinal Pathology in a Mouse Model of Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2019 , 56, 6017-6034	6.2	23	
Š	96	First behavioural assessment of a novel Immp2l knockdown mouse model with relevance for Gilles de la Tourette syndrome and Autism spectrum disorder. <i>Behavioural Brain Research</i> , 2019 , 374, 112057	3.4	6	
Ş	95	Cannabidiol (CBD) reduces anxiety-related behavior in mice via an FMRP-independent mechanism. <i>Pharmacology Biochemistry and Behavior</i> , 2019 , 181, 93-100	3.9	19	
٥	94	Chronic Microglial Activation in the GFAP-IL6 Mouse Contributes to Age-Dependent Cerebellar Volume Loss and Impairment in Motor Function. <i>Frontiers in Neuroscience</i> , 2019 , 13, 303	5.1	19	
Ş	93	Targeting Inflammatory Pathways in Alzheimer's Disease: A Focus on Natural Products and Phytomedicines. CNS Drugs, 2019, 33, 457-480	6.7	15	
٥	92	Behavioural effects of high fat diet exposure starting in late adolescence in neuregulin 1 transmembrane domain mutant mice. <i>Behavioural Brain Research</i> , 2019 , 373, 112074	3.4	2	
Ş	91	Sphingosine Kinase 2 Potentiates Amyloid Deposition but Protects against Hippocampal Volume Loss and Demyelination in a Mouse Model of Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2019 , 39, 9645-9659	6.6	14	
ç	90	Long-term behavioural effects of maternal obesity in C57BL/6J mice. <i>Physiology and Behavior</i> , 2019 , 199, 306-313	3.5	17	
8	89	Assessment of diets containing curcumin, epigallocatechin-3-gallate, docosahexaenoic acid and Elipoic acid on amyloid load and inflammation in a male transgenic mouse model of Alzheimer's disease: Are combinations more effective?. <i>Neurobiology of Disease</i> , 2019 , 124, 505-519	7.5	25	
8	38	Neuregulin 1 Deficiency Modulates Adolescent Stress-Induced Dendritic Spine Loss in a Brain Region-Specific Manner and Increases Complement 4 Expression in the Hippocampus. <i>Schizophrenia Bulletin</i> , 2019 , 45, 339-349	1.3	11	
8	87	Effect of Fluvoxamine on Amyloid-Peptide Generation and Memory. <i>Journal of Alzheimers Disease</i> , 2018 , 62, 1777-1787	4.3	4	
8	86	Schizophrenia-relevant behaviours of female mice overexpressing neuregulin 1 type III. <i>Behavioural Brain Research</i> , 2018 , 353, 227-235	3.4	16	
8	85	Overexpression of Neuregulin 1 Type III Confers Hippocampal mRNA Alterations and Schizophrenia-Like Behaviors in Mice. <i>Schizophrenia Bulletin</i> , 2018 , 44, 865-875	1.3	15	
8	84	The Endocannabinoid System across Postnatal Development in Transmembrane Domain Mutant Mice. <i>Frontiers in Psychiatry</i> , 2018 , 9, 11	5	5	

83	Reduced type III neuregulin 1 expression does not modulate the behavioural sensitivity of mice to acute Etetrahydrocannabinol (D-THC). <i>Pharmacology Biochemistry and Behavior</i> , 2018 , 170, 64-70	3.9	4
82	Cannabinoid Modulation of Object Recognition and Location Memory Preclinical Assessment. <i>Handbook of Behavioral Neuroscience</i> , 2018 , 27, 461-488	0.7	1
81	Diet-induced adaptive thermogenesis requires neuropeptide FF receptor-2 signalling. <i>Nature Communications</i> , 2018 , 9, 4722	17.4	30
80	Mouse models of frontotemporal dementia: A comparison of phenotypes with clinical symptomatology. <i>Neuroscience and Biobehavioral Reviews</i> , 2017 , 74, 126-138	9	18
79	The therapeutic potential of the phytocannabinoid cannabidiol for Alzheimer's disease. <i>Behavioural Pharmacology</i> , 2017 , 28, 142-160	2.4	26
78	Contextual fear conditioning is enhanced in mice lacking functional sphingosine kinase 2. <i>Behavioural Brain Research</i> , 2017 , 333, 9-16	3.4	9
77	First Behavioural Characterisation of a Knockout Mouse Model for the Transforming Growth Factor (TGF)-Buperfamily Cytokine, MIC-1/GDF15. <i>PLoS ONE</i> , 2017 , 12, e0168416	3.7	6
76	The Interactive Nature of Cannabis and Schizophrenia Risk Genes 2017 , 335-344		2
75	Molecular Basis of Cannabis-Induced Schizophrenia-Relevant Behaviours: Insights from Animal Models. <i>Current Behavioral Neuroscience Reports</i> , 2017 , 4, 254-279	1.7	3
74	Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer Disease. Frontiers in Pharmacology, 2017, 8, 20	5.6	86
73	Parent-of-origin effects on schizophrenia-relevant behaviours of type III neuregulin 1 mutant mice. <i>Behavioural Brain Research</i> , 2017 , 332, 250-258	3.4	5
72	Disinhibition-like behavior in a P301S mutant tau transgenic mouse model of frontotemporal dementia. <i>Neuroscience Letters</i> , 2016 , 631, 24-29	3.3	28
71	Neuregulin-1 and schizophrenia in the genome-wide association study era. <i>Neuroscience and Biobehavioral Reviews</i> , 2016 , 68, 387-409	9	50
70	Cerebral Apolipoprotein-D Is Hypoglycosylated Compared to Peripheral Tissues and Is Variably Expressed in Mouse and Human Brain Regions. <i>PLoS ONE</i> , 2016 , 11, e0148238	3.7	10
69	Genetic Rat Models for Schizophrenia. <i>Handbook of Behavioral Neuroscience</i> , 2016 , 23, 303-324	0.7	2
68	Behavioural effects of high fat diet in a mutant mouse model for the schizophrenia risk gene neuregulin 1. <i>Genes, Brain and Behavior</i> , 2016 , 15, 295-304	3.6	6
67	Abca7 deletion does not affect adult neurogenesis in the mouse. <i>Bioscience Reports</i> , 2016 , 36,	4.1	3
66	Neuregulin 1 Prevents Phencyclidine-Induced Behavioral Impairments and Disruptions to GABAergic Signaling in Mice. <i>International Journal of Neuropsychopharmacology</i> , 2015 , 18, pyu114	5.8	13

(2013-2015)

65	Understanding the function of ABCA7 in Alzheimer's disease. <i>Biochemical Society Transactions</i> , 2015 , 43, 920-3	5.1	33
64	Septal Glucagon-Like Peptide 1 Receptor Expression Determines Suppression of Cocaine-Induced Behavior. <i>Neuropsychopharmacology</i> , 2015 , 40, 1969-78	8.7	55
63	Apolipoprotein D modulates amyloid pathology in APP/PS1 Alzheimer\$ disease mice. <i>Neurobiology of Aging</i> , 2015 , 36, 1820-33	5.6	27
62	Testosterone attenuates and the selective estrogen receptor modulator, raloxifene, potentiates amphetamine-induced locomotion in male rats. <i>Hormones and Behavior</i> , 2015 , 70, 73-84	3.7	12
61	Behavioural characteristics of the Prader-Willi syndrome related biallelic Snord116 mouse model. <i>Neuropeptides</i> , 2015 , 53, 71-7	3.3	17
60	Neuregulin 1 expression and electrophysiological abnormalities in the Neuregulin 1 transmembrane domain heterozygous mutant mouse. <i>PLoS ONE</i> , 2015 , 10, e0124114	3.7	15
59	Chronic cannabidiol treatment improves social and object recognition in double transgenic APPswe/PS1E9 mice. <i>Psychopharmacology</i> , 2014 , 231, 3009-17	4.7	84
58	Long-term cannabidiol treatment prevents the development of social recognition memory deficits in Alzheimer's disease transgenic mice. <i>Journal of Alzheimer's Disease</i> , 2014 , 42, 1383-96	4.3	91
57	Partial genetic deletion of neuregulin 1 modulates the effects of stress on sensorimotor gating, dendritic morphology, and HPA axis activity in adolescent mice. <i>Schizophrenia Bulletin</i> , 2014 , 40, 1272-8	41.3	26
56	Novel behavioural characteristics of female APPSwe/PS1 E 9 double transgenic mice. <i>Behavioural Brain Research</i> , 2014 , 260, 111-8	3.4	36
55	Effect of maternal immune activation on the kynurenine pathway in preadolescent rat offspring and on MK801-induced hyperlocomotion in adulthood: amelioration by COX-2 inhibition. <i>Brain, Behavior, and Immunity</i> , 2014 , 41, 173-81	16.6	33
54	Schizophrenia: a consequence of gene-environment interactions?. <i>Frontiers in Behavioral Neuroscience</i> , 2014 , 8, 435	3.5	19
53	Neuropeptide y attenuates stress-induced bone loss through suppression of noradrenaline circuits. Journal of Bone and Mineral Research, 2014 , 29, 2238-49	6.3	43
52	Do individually ventilated cage systems generate a problem for genetic mouse model research?. <i>Genes, Brain and Behavior</i> , 2014 , 13, 713-20	3.6	17
51	A neuregulin 1 transmembrane domain mutation causes imbalanced glutamatergic and dopaminergic receptor expression in mice. <i>Neuroscience</i> , 2013 , 248, 670-80	3.9	30
50	Behavioural consequences of IVC cages on male and female C57BL/6J mice. <i>Neuroscience</i> , 2013 , 237, 285-93	3.9	33
49	Novel behavioural characteristics of the APP(Swe)/PS1E9 transgenic mouse model of Alzheimer's disease. <i>Behavioural Brain Research</i> , 2013 , 245, 120-7	3.4	44
48	Female neuregulin 1 heterozygous mice require repeated exposure to Eetrahydrocannabinol to alter sensorimotor gating function. <i>Pharmacopsychiatry</i> , 2013 , 46, 286-91	2	4

47	Deletion of Abca7 increases cerebral amyloid-laccumulation in the J20 mouse model of Alzheimers disease. <i>Journal of Neuroscience</i> , 2013 , 33, 4387-94	6.6	141
46	Transmembrane domain Nrg1 mutant mice show altered susceptibility to the neurobehavioural actions of repeated THC exposure in adolescence. <i>International Journal of Neuropsychopharmacology</i> , 2013 , 16, 163-75	5.8	58
45	Neuregulin 1: a prime candidate for research into gene-environment interactions in schizophrenia? Insights from genetic rodent models. <i>Frontiers in Behavioral Neuroscience</i> , 2013 , 7, 106	3.5	28
44	Novel molecular changes induced by Nrg1 hypomorphism and Nrg1-cannabinoid interaction in adolescence: a hippocampal proteomic study in mice. <i>Frontiers in Cellular Neuroscience</i> , 2013 , 7, 15	6.1	30
43	What does a mouse tell us about neuregulin 1-cannabis interactions?. <i>Frontiers in Cellular Neuroscience</i> , 2013 , 7, 18	6.1	14
42	The response of neuregulin 1 mutant mice to acute restraint stress. <i>Neuroscience Letters</i> , 2012 , 515, 82-6	3.3	19
41	Cognition in female transmembrane domain neuregulin 1 mutant mice. <i>Behavioural Brain Research</i> , 2012 , 226, 218-23	3.4	42
40	Cognitive phenotyping of amyloid precursor protein transgenic J20 mice. <i>Behavioural Brain Research</i> , 2012 , 228, 392-7	3.4	35
39	The therapeutic potential of the endocannabinoid system for Alzheimer's disease. <i>Expert Opinion on Therapeutic Targets</i> , 2012 , 16, 407-20	6.4	26
38	Distinct neurobehavioural effects of cannabidiol in transmembrane domain neuregulin 1 mutant mice. <i>PLoS ONE</i> , 2012 , 7, e34129	3.7	65
37	The yin and yang of cannabis-induced psychosis: the actions of (P)-tetrahydrocannabinol and cannabidiol in rodent models of schizophrenia. <i>Current Pharmaceutical Design</i> , 2012 , 18, 5113-30	3.3	36
36	Role of Abca7 in mouse behaviours relevant to neurodegenerative diseases. <i>PLoS ONE</i> , 2012 , 7, e45959	3.7	32
35	Do transmembrane domain neuregulin 1 mutant mice exhibit a reliable sensorimotor gating deficit?. <i>Behavioural Brain Research</i> , 2011 , 223, 336-41	3.4	48
34	Cannabidiol potentiates Letrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats. <i>Psychopharmacology</i> , 2011 , 218, 443-57	4.7	132
33	The schizophrenia susceptibility gene neuregulin 1 modulates tolerance to the effects of cannabinoids. <i>International Journal of Neuropsychopharmacology</i> , 2011 , 14, 631-43	5.8	54
32	Schizophrenia-relevant behaviours in a genetic mouse model for Y2 deficiency. <i>Behavioural Brain Research</i> , 2010 , 207, 434-40	3.4	22
31	Cognition in transmembrane domain neuregulin 1 mutant mice. <i>Neuroscience</i> , 2010 , 170, 800-7	3.9	82
30	A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. <i>International Journal of Neuropsychopharmacology</i> , 2010 , 13, 861-76	5.8	131

(2006-2010)

29	A follow-up study: acute behavioural effects of Delta(9)-THC in female heterozygous neuregulin 1 transmembrane domain mutant mice. <i>Psychopharmacology</i> , 2010 , 211, 277-89	4.7	54
28	A transgenic mouse model of spinocerebellar ataxia type 3 resembling late disease onset and gender-specific instability of CAG repeats. <i>Neurobiology of Disease</i> , 2010 , 37, 284-93	7.5	47
27	Acoustic startle response and sensorimotor gating in a genetic mouse model for the Y1 receptor. <i>Neuropeptides</i> , 2010 , 44, 233-9	3.3	10
26	Obesity and the associated mediators leptin, estrogen and IGF-I enhance the cell proliferation and early tumorigenesis of breast cancer cells. <i>Nutrition and Cancer</i> , 2009 , 61, 484-91	2.8	33
25	Neuregulin 1 hypomorphic mutant mice: enhanced baseline locomotor activity but normal psychotropic drug-induced hyperlocomotion and prepulse inhibition regulation. <i>International Journal of Neuropsychopharmacology</i> , 2009 , 12, 1383-93	5.8	8o
24	Y1 receptors are critical for the proliferation of adult mouse precursor cells in the olfactory neuroepithelium. <i>Journal of Neurochemistry</i> , 2008 , 105, 641-52	6	39
23	Behavioural profile of a new mouse model for NPY deficiency. <i>European Journal of Neuroscience</i> , 2008 , 28, 173-80	3.5	102
22	Increased levels of serotonin 2A receptors and serotonin transporter in the CNS of neuregulin 1 hypomorphic/mutant mice. <i>Schizophrenia Research</i> , 2008 , 99, 341-9	3.6	38
21	Behavioral profile of a heterozygous mutant mouse model for EGF-like domain neuregulin 1. <i>Behavioral Neuroscience</i> , 2008 , 122, 748-59	2.1	53
20	Altered motor activity, exploration and anxiety in heterozygous neuregulin 1 mutant mice: implications for understanding schizophrenia. <i>Genes, Brain and Behavior</i> , 2007 , 6, 677-87	3.6	140
19	Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of Delta9-tetrahydrocannabinol. <i>Psychopharmacology</i> , 2007 , 192, 325-36	4.7	147
18	Dynorphin knockout reduces fat mass and increases weight loss during fasting in mice. <i>Molecular Endocrinology</i> , 2007 , 21, 1722-35		26
17	Behavioral profiling of NPY in aggression and neuropsychiatric diseases. <i>Peptides</i> , 2007 , 28, 326-33	3.8	58
16	Neuropeptide Y (NPY) cleaving enzymes: structural and functional homologues of dipeptidyl peptidase 4. <i>Peptides</i> , 2007 , 28, 257-68	3.8	69
15	Heterozygous neuregulin 1 mice display greater baseline and Delta(9)-tetrahydrocannabinol-induced c-Fos expression. <i>Neuroscience</i> , 2007 , 149, 861-70	3.9	68
14	Peptide YY ablation in mice leads to the development of hyperinsulinaemia and obesity. <i>Diabetologia</i> , 2006 , 49, 1360-70	10.3	139
13	Effects of chronic risperidone treatment on the striatal protein profiles in rats. <i>Brain Research</i> , 2006 , 1113, 24-32	3.7	29
12	Stress-induced hyperthermia in the rat: comparison of classical and novel recording methods. <i>Laboratory Animals</i> , 2006 , 40, 186-93	2.6	44

11.5

3.2

3.9

3.5

74

13

234

42

51

44

8	deficiency in mice. <i>Diabetes</i> , 2006 , 55, 19-26	0.9
	V1 secondary regulate aggressive helpovies by modulating secondary pathways. Organidary of the	

Y1 receptors regulate aggressive behavior by modulating serotonin pathways. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 12742-7

Distinct endocrine effects of chronic haloperidol or risperidone administration in male rats.

PP, PYY and NPY: Synthesis, Storage, Release and Degradation. Handbook of Experimental Pharmacology, **2004**, 23-44

Behavioral phenotyping of mice in pharmacological and toxicological research. Experimental and *Toxicologic Pathology*, **2003**, 55, 69-83

Behavioral effects of neuropeptide Y in F344 rat substrains with a reduced dipeptidyl-peptidase IV activity. Pharmacology Biochemistry and Behavior, 2003, 75, 869-79

Extreme reduction of dipeptidyl peptidase IV activity in F344 rat substrains is associated with various behavioral differences. Physiology and Behavior, 2003, 80, 123-34

Localization, transmission, spontaneous mutations, and variation of function of the Dpp4 (Dipeptidyl-peptidase IV; CD26) gene in rats. Regulatory Peptides, 2003, 115, 81-90

Cannabis abuse and dependence315-329

11

10

9

6

5

Research, 2006, 167, 87-93

Research, 2006, 171, 286-94

Neuropharmacology, **2006**, 51, 1129-36